Form 4: Sarepta Grants EVP Cristin Rothfuss 118,875 RSUs

Sarepta Therapeutics granted its EVP and General Counsel, Cristin Rothfuss, 118,875 restricted stock units, vesting over several years.

Summary

• Cristin Rothfuss, Executive Vice President and General Counsel of Sarepta Therapeutics, Inc. (SRPT), was granted a total of 118,875 Restricted Stock Units (RSUs) on September 3, 2025.
• The grant includes 93,875 RSUs, with 50% scheduled to vest on September 3, 2026, and the remaining 50% on September 3, 2027, contingent on continued service.
• An additional 25,000 RSUs were granted, which will vest 100% on September 3, 2028, subject to continued service and the achievement of specific performance criteria determined by the Compensation Committee of the Board.
• Following these transactions, Ms. Rothfuss beneficially owns 139,985 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive signal for aligning management and shareholder interests, indicating confidence in future performance and executive retention. It is a routine compensation event and does not reflect a significant change in company operations or financial health.

Positives

• The grant of Restricted Stock Units (RSUs) to a key executive like Cristin Rothfuss aligns her long-term financial interests with those of Sarepta Therapeutics' shareholders, incentivizing sustained company performance.
• A portion of the RSU grant (25,000 units) is performance-based, directly linking executive compensation to the achievement of specific company goals, which can drive strategic execution.

Negatives

• The RSUs do not provide immediate cash value to the executive, as they are subject to vesting conditions over several years.
• The full realization of the RSU value is contingent on Ms. Rothfuss's continued service to the company and, for a portion, on the achievement of specific performance criteria.

Risks

• The vesting of 25,000 RSUs is subject to the achievement of certain performance criteria, which may not be met, potentially reducing the executive's realized compensation.
• The ultimate value of the RSUs upon vesting is dependent on the future market price of Sarepta Therapeutics' common stock, which is subject to market volatility and company performance.

Future Outlook

The multi-year vesting schedule for the RSU grants indicates a long-term commitment from Sarepta Therapeutics to retain and incentivize its EVP, General Counsel, Cristin Rothfuss, aligning her future compensation with the company's sustained performance and stock appreciation.

Industry Context

Equity-based compensation, such as Restricted Stock Units (RSUs), is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives. This grant is consistent with typical executive compensation structures in the sector, aiming to align management incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The RSU grant to a senior executive like an EVP and General Counsel is a common compensation strategy across publicly traded companies, particularly in the high-growth biotech sector.
• Companies such as Biogen (BIIB), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) frequently utilize similar equity incentive programs to reward and retain top talent, ensuring their interests are aligned with company performance and shareholder returns.
• The multi-year vesting schedule and performance-based components are also standard features designed to promote long-term commitment and achievement of strategic goals within the industry.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent within the company.

Next Steps

• Vesting of 93,875 RSUs: 50% on September 3, 2026, and 50% on September 3, 2027, subject to continued service.
• Vesting of 25,000 RSUs: 100% on September 3, 2028, subject to continued service and achievement of performance criteria.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a senior executive. While it aligns executive interests with shareholders, it does not present new material information regarding the company's operational performance, financial outlook, or strategic direction that would warrant a change in investment recommendation. It is a standard compensation event.

Keywords

Sarepta Therapeutics, SRPT, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Cristin Rothfuss, Equity Grant, Biotechnology